A detailed history of Lpl Financial LLC transactions in Ardelyx, Inc. stock. As of the latest transaction made, Lpl Financial LLC holds 197,366 shares of ARDX stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
197,366
Previous 193,054 2.23%
Holding current value
$1.02 Million
Previous $1.43 Million 4.97%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$5.28 - $7.57 $22,767 - $32,641
4,312 Added 2.23%
197,366 $1.36 Million
Q2 2024

Aug 07, 2024

BUY
$5.89 - $9.31 $376,477 - $595,076
63,918 Added 49.5%
193,054 $1.43 Million
Q1 2024

May 10, 2024

BUY
$6.05 - $9.74 $152,460 - $245,448
25,200 Added 24.25%
129,136 $942,000
Q4 2023

Feb 14, 2024

BUY
$3.29 - $6.64 $58,196 - $117,454
17,689 Added 20.51%
103,936 $644,000
Q3 2023

Nov 13, 2023

BUY
$3.3 - $4.83 $21,176 - $30,994
6,417 Added 8.04%
86,247 $351,000
Q2 2023

Jul 31, 2023

BUY
$3.23 - $4.95 $19,799 - $30,343
6,130 Added 8.32%
79,830 $270,000
Q1 2023

May 10, 2023

BUY
$2.68 - $4.79 $38,056 - $68,018
14,200 Added 23.87%
73,700 $353,000
Q4 2022

Feb 07, 2023

SELL
$1.22 - $2.85 $3,660 - $8,550
-3,000 Reduced 4.8%
59,500 $169,000
Q3 2022

Nov 14, 2022

BUY
$0.59 - $1.44 $8,260 - $20,160
14,000 Added 28.87%
62,500 $74,000
Q2 2022

Aug 12, 2022

BUY
$0.51 - $1.17 $51 - $117
100 Added 0.21%
48,500 $29,000
Q1 2022

May 16, 2022

BUY
$0.65 - $1.18 $15,600 - $28,320
24,000 Added 98.36%
48,400 $52,000
Q4 2021

Feb 14, 2022

BUY
$0.86 - $1.7 $7,912 - $15,640
9,200 Added 60.53%
24,400 $27,000
Q3 2021

Nov 15, 2021

BUY
$1.27 - $8.17 $19,304 - $124,184
15,200 New
15,200 $20,000

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $799M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Lpl Financial LLC Portfolio

Follow Lpl Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.